A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients...
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer-Verlag
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer-Verlag
Subjects
More information
Scope and Contents
Contents
Purpose
We conducted a phase II study to evaluate the efficacy and safety of a triplet regimen of docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer.
Methods
Docetaxel (40 mg/m
2
) and cisplatin (70 or 60 mg/m
2
) were given on day 1 of a 28-day cycle. S-1 (40 mg/m
2
) was given twice...
Alternative Titles
Full title
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_917944258
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_917944258
Other Identifiers
ISSN
0344-5704
E-ISSN
1432-0843
DOI
10.1007/s00280-011-1701-1
